Latest news and publications
On 19th November 2024, Microbira’s CEO, Marianne Ismail, was among the distinguished attendees at the Cross-Party Group (CPG) on Life Sciences meeting, held at the Scottish Parliament. The event, convened by Kenneth Gibson MSP, brought together key leaders in the life sciences field to discuss pivotal advancements and strategies for addressing global health challenges.
As the life sciences community continues to push boundaries, Microbira’s presence at events like the CPG meeting highlights its role as a forward-thinking leader in diagnostics and biotechnology.
Last week, during Antimicrobial Resistance (AMR) Awareness Week, there was a global effort to raise awareness about one of the most pressing public health challenges. AMR occurs when bacteria, viruses, fungi, and parasites evolve to resist the effects of medicines, making infections more difficult to treat and increasing the risk of severe illness and death.
The simplicity and efficiency of our platform empower healthcare providers to make informed decisions, advancing the fight against AMR. Last week reminded us all that collaboration across healthcare, research, and innovation is essential to ensuring that life-saving treatments remain effective for future generations.
Microbira is excited to announce that we have progressed to the second stage of SBRI Healthcare’s Competition 25: Accelerating Innovations to Tackle Antimicrobial Resistance (AMR)! The project aims to leverage existing NHS pathways to improve diagnostics, ensuring greater accessibility and equity in healthcare.
Fingers crossed as we await the results—we’re optimistic about the opportunity to further this project and make a lasting impact on diagnostics in healthcare systems. Stay tuned for updates!
Microbira was honored to participate in the Women’s Health Event hosted in Edinburgh on 12th September, in collaboration with Burness Paull and the Scottish Life Sciences Association. The event featured a strong lineup of speakers addressing advancements in reproductive medicine, pharmaceutical innovations, menopause research, and the role of diversity and inclusion in corporate settings.
The discussions offered invaluable insights from industry-leading experts. We extend our gratitude to the organisers, for creating such an impactful forum. Microbira is proud to be part of these important conversations and looks forward to continuing to support initiatives that champion women’s health.
Microbira took part in Innovate UK’s Global Business Innovation Programme (GBIP) focused on Antimicrobial Resistance (AMR) in India. This program provided us with a unique opportunity to engage with stakeholders across India’s thriving AMR ecosystem, including innovators, policymakers, and industry leaders.
We look forward to leveraging this platform to strengthen partnerships, share expertise, and contribute to global efforts in addressing the AMR challenge. Stay tuned for updates on our journey and insights from this exciting initiative!
We are very excited to announce our selection and participation in Innovate UK’s Global Business Innovation Programme (GBIP) focused on Antimicrobial Resistance. We joined a delegation representing some of the UK’s most exciting Diagnostics, Therapeutics, Preventative and Vaccines to visit Switzerland.
Marianne Ismail, CEO of Microbira had the opportunity to open the Diagnostics Pipeline Corner at the annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Denmark. The ECCMID Diagnostics Pipeline Corner is a popular session type for small and medium-sized enterprises globally to showcase their ongoing research and products. Marianne presented the latest version of Microbira Advanced Analytical Platform – Infrared (MAAP-IR) and results from our ongoing collaboration with NHS North East Innovation Lab and other laboratories.
OCC: We worked alongside Microbira to successfully deliver an enhanced web application of their existing researcher toolkit.
“From the time Microbira was introduced to OCC by our Clinical Consulting Company, the team at OCC grasped our project needs immediately. We wanted a reputable company that would be familiar with clinical software development and process from the lab to commercialisation with the required regulatory approvals.”
Scientists at a Newcastle laboratory have played a key role in supporting the development of a new test which could use artificial intelligence to detect microbes that cause illnesses like Strep A and E. coli.
The team at the North East Innovation Lab – part of the Newcastle Hospitals NHS Trust – have been working with firm Microbira Ltd to help test the company’s predictive software which can work out what infections may be afflicting a patient. The lab team have been helping to expand the data used by the software.
The Microbira project supports new artificial intelligence techniques to diagnose infection and improve patient outcomes.
The system uses artificial intelligence (AI) to quickly detect and identify infective microorganisms such as bacteria and clinical yeasts which cause human infection and disease.
Examples include E. coli O157 which can cause outbreaks of sickness after consumption of contaminated food/water…